The Zacks Analyst Blog Highlights: Abbott Labs, Bristol-Myers Squibb, Biogen ... Sacramento Bee Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Another promising pipeline candidate is bardoxolone, which moved into phase III studies ... |
